CYP17A1 and Familial prostate cancer: For prostate cancer, the expression of the AR-V7 RNA in CTCs was identified as a predictive marker for response to enzalutamide (anti-androgen) and abiraterone (anti-androgen and CYP17 inhibitor) [61].